Shuyan Li1
Guanze Li2*- 1The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
- 2Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
1 Introduction
While Krasny et al. (1) offer important insights into the use of DNA vaccines for treating platinum-resistant ovarian cancer, several methodological limitations must be carefully considered to inform the further development of DNA vaccine-based interventions. The results of this randomized controlled trial (RCT) are clinically encouraging; however, the study’s implementation revealed conceptual and technical limitations that warrant scholarly discussion to guide the design of more robust future trials.
2 Critical methodological challenges
2.1 Sample size and geographic representation
With a sample size of merely 40 patients and data collected exclusively from a single country, this study’s results should be interpreted with caution. The limited scale and geographic restriction may constrain the generalizability of the findings, making it difficult to extrapolate the outcomes to more diverse populations with varying demographic and genetic backgrounds.
2.2 Follow-up duration
Given a median follow-up of only 13.8 months, the current study may not fully capture long-term outcomes, particularly regarding the durability of treatment responses and the occurrence of serious or late-onset adverse events. Future studies with extended follow-up are likely to provide more reliable and clinically meaningful data.
3 Novel perspectives for future research
3.1 Open-label design considerations
The open-label nature of this trial, though ethically necessary, may introduce both conscious and unconscious biases in outcome assessment, thereby increasing variability in the reported results. Future studies could address these limitations by employing independent blinded reviews or other methodological safeguards to ensure a more objective and reliable endpoint evaluation.
3.2 Additional clinical endpoints and biomarker
In order to provide a more comprehensive evaluation of therapeutic benefit, future studies could consider incorporating additional clinically relevant endpoints, including overall survival (OS), in addition to progression-free survival (PFS) and objective response rate. This approach aligns with the design of numerous related RCT (2), many of which have adopted OS as a key endpoint to better assess long-term outcomes.
Moreover, the article suggests that ELENAGEN not only enhances antitumor immune activation but also reduces chronic inflammation, thereby improving the efficacy of chemotherapy. Therefore, collecting data on inflammatory markers such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in future studies will be essential to elucidate inflammation-related mechanisms.
3.3 BRCA mutation data collection
We recommend collecting detailed data on BRCA mutation types among patients. Analyzing outcomes stratified by BRCA status could reveal differences in treatment response and inform more personalized therapeutic strategies. Notably, recent RCT (3) have shown that various BRCA mutation subtypes may respond differently to specific treatment modalities, emphasizing the clinical relevance of mutation-specific data. This study suggests that continuous dosing may confer a potential progression-free survival benefit in patients with gBRCA wild-type or unknown status.
A previous study (4) has demonstrated that BRCA2 mutations are significantly associated with poorer OS, highlighting the need for this investigation.
3.4 Insufficient animal evidence for ovarian cancer
In previous studies (5), the p26 vaccine demonstrated antitumor efficacy and an absence of toxicity in animal models of Lewis lung carcinoma, B16 melanoma, S37 sarcoma, and Ca755 breast cancer. However, no preclinical experiments have been conducted using ovarian cancer models. Although multiple genomic studies from different countries have demonstrated that ovarian and breast cancers share similarities in genetic mutations and molecular signaling pathways (6, 7), important differences remain in their clinical management (8, 9).
4 Discussion
In conclusion, this study provides valuable preliminary evidence on the efficacy of DNA vaccines in platinum-resistant ovarian cancer. Future trials could expand patient cohorts across multiple regions to enhance generalizability and include longer follow-up to better assess long-term outcomes. Incorporating additional endpoints, such as overall survival and objective response rate, would provide a more comprehensive evaluation of therapeutic benefit. Collecting detailed BRCA mutation data may help identify subgroups most likely to benefit and guide personalized strategies. Additionally, implementing independent blinded assessments could improve reliability and reduce potential bias. These approaches will collectively help optimize the design and impact of DNA vaccine-based interventions in ovarian cancer. Given that the current clinical trial has been completed, several of these assessments, including biomarker evaluation, should be considered for inclusion in subsequent follow-up studies to further clarify the drug’s biological effects. Thank you for considering these observations, and I look forward to further developments in this promising field.
Author contributions
SL: Conceptualization, Formal Analysis, Investigation, Validation, Writing – original draft, Writing – review & editing. GL: Investigation, Project administration, Supervision, Validation, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Acknowledgments
We sincerely thank Krasny et al. for their valuable contribution to advancing research on DNA vaccines in ovarian cancer. Their work provides an important foundation for further investigation and discussion in this evolving field.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
IL-6, interleukin-6; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; TNF-α, tumor necrosis factor-alpha.
References
1. Krasny S, Baranau Y, Polyakov S, Zharkova E, Streltsova O, Filimonava A, et al. Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial. Front Oncol. (2024) 14:1343023. doi: 10.3389/fonc.2024.1343023
2. Lee JM, Miller A, Rose PG, AlHilli M, Washington C, John VS, et al. Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial. Clin Cancer Res. (2025) 31:2370–8. doi: 10.1158/1078-0432.CCR-24-3877
3. Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, et al. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer. Gynecol Oncol. (2022) 164:505–13. doi: 10.1016/j.ygyno.2022.01.015
4. Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. (2016) 7:70113–27. doi: 10.18632/oncotarget.12158
5. Venanzi F, Shifrin V, Sherman M, Gabai V, Kiselev O, Komissarov A, et al. Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget. (2013) 4:1829–35. doi: 10.18632/oncotarget.1397
6. Gao X, Nan X, Liu Y, Liu R, Zang W, Shan G, et al. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. Hum Mutat. (2020) 41:696–708. doi: 10.1002/humu.23965
7. Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, and Maillet P. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Dis Markers. (2012) 32:343–53. doi: 10.1155/2012/234136
8. An J, Peng C, Xie X, and Peng F. New advances in targeted therapy of HER2-negative breast cancer. Front Oncol. (2022) 12:828438. doi: 10.3389/fonc.2022.828438
Keywords: ovarian cancer, ELENAGEN, commentary, randomized controlled trial, BRCA
Citation: Li S and Li G (2025) Commentary: Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial. Front. Oncol. 15:1727892. doi: 10.3389/fonc.2025.1727892
Received: 18 October 2025; Accepted: 19 November 2025; Revised: 14 November 2025;
Published: 05 December 2025.
Edited by:
Hanlin Ou, Qingdao University, ChinaReviewed by:
Ruitong Xu, Nanjing Medical University, ChinaFeng Xiaodi, Qingdao Haici Hospital, China
Copyright © 2025 Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guanze Li, TGlfZ3VhbnplQDE2My5jb20=